Nom du produit:8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

IUPAC Name:8-chloro-2-(methylsulfanyl)pyrimido[5,4-d][1,3]diazine

CAS:176637-10-8
Formule moléculaire:C7H5ClN4S
Pureté:95%+
Numéro de catalogue:CM167362
Poids moléculaire:212.66

Unité d'emballage Stock disponible Prix($) Quantité
CM167362-250mg in stock ǤȎư
CM167362-500mg in stock ʼnĽʼn
CM167362-1g in stock ĽŢĽ
CM167362-5g 1-2 Weeks Ǥůưư
CM167362-10g 1-2 Weeks ǵʼnưů

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:176637-10-8
Formule moléculaire:C7H5ClN4S
Point de fusion:-
Code SMILES:CSC1=NC=C(N=CN=C2Cl)C2=N1
Densité:
Numéro de catalogue:CM167362
Poids moléculaire:212.66
Point d'ébullition:
N° Mdl:MFCD00227587
Stockage:Store at 2-8°C.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Related Products